|Bid||3.96 x 800|
|Ask||3.97 x 800|
|Day's Range||3.8000 - 4.0600|
|52 Week Range||2.3400 - 9.9250|
|Beta (3Y Monthly)||0.63|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.00|
On Sangamo (SGMO) Q4 conference call, investors will look into genome editing development and gene regulation technology platform, used for inventing genomic therapies to address unmet medical needs.
NEW YORK, Feb. 14, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Aduro (ADRO) doses the first patient in a phase I study on ADU-S100 in combination with Yervoy for the treatment of relapsed and refractory melanoma. Shares rise.
Zoetis Inc. (ZTS) is gearing up to report fourth-quarter 2018 results. The company continues to strengthen its diverse product portfolio through lifecycle innovations, strong customer relationships, and access to new markets and technologies.
Merrimack (MACK) regains its status as a development-stage biopharma company after the sale of its sole marketed product Onivyde in 2017.
Aduro Biotech, Inc. (ADRO) today announced that the first patient has been dosed in a Phase 1 trial of ADU-S100 (MIW815), a novel stimulator of interferon genes (STING) pathway activator, in combination with YERVOY® (ipilimumab), an approved anti-CTLA-4 antibody for the treatment of relapsed and refractory melanoma. The multicenter trial (see www.clinicaltrials.gov, identifier: NCT02675439), which is part of an ongoing research and development collaboration with Novartis, will enroll advanced melanoma patients who have relapsed after or are refractory to treatment with anti-PD-1 antibodies, nivolumab or pembrolizumab. “We are pleased to initiate this study evaluating ADU-S100 with ipilimumab in a homogeneous patient population.
Biotech companies' reasons differ for 600 job cuts over the past few months, but the numbers are jarring for an industry at the intersection of a strong cash position and groundbreaking science.
Aduro Biotech, Inc. (ADRO) today announced a strategic reset to focus on Aduro’s core strengths – discovery and development of novel product candidates in the stimulator of interferon genes (STING) and a proliferation inducing ligand (APRIL) pathways. Aduro is partnered with Novartis for STING pathway activators in oncology, including ADU-S100 (MIW815), and Eli Lilly and Company (Lilly) for cGAS-STING pathway inhibitors in autoimmune and inflammatory diseases. BION-1301, a first-in-class anti-APRIL antibody, is currently in development in oncology and IgA nephropathy.
If you're interested in Aduro BioTech, Inc. (NASDAQ:ADRO), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could Read More...
Athersys (ATHX) gains on encouraging results from its exploratory study on the intravenous administration of MultiStem cell therapy to treat patients suffering from ARDS.
Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.
Amicus (FOLD) is well placed after the United States approved its only marketed drug, Galafold, and the company added 14 new gene therapy programs to its pipeline for rare metabolic diseases.
Aduro Biotech (ADRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
BERKELEY, Calif., Jan. 03, 2019 -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is.
With hotel stays during next month's J.P. Morgan Healthcare Conference and other nearby events reaching five figures, some wonder if small biotechs are being priced out of San Francisco's big week of meetings with companies and investors.
Zero-debt allows substantial financial flexibility, especially for small-cap companies like Aduro BioTech, Inc. (NASDAQ:ADRO), as the company does not have to adhere to strict debt covenants. However, it also faces Read More...